RESUMO
Clinical efficacy and safety of tanakan has been studied in 30 patients with the syndrome of mild cognitive impairment. The results suggest a clear therapeutic effect of the 6 month course therapy. The efficacy of tanakan was confirmed by significant improvement of cognitive functioning of patients measured with MMSE, MDRS, FAST and other scales. The feature of tanakan effect is its positive influence on memory and other cognitive functions that allows the use of the drug in the treatment of elderly people with the syndrome of mild cognitive impairment. The safety of tanakan used in high therapeutic dosages (240 mg daily) and its good tolerability during chronic administration are revealed.
Assuntos
Transtornos Cognitivos/tratamento farmacológico , Extratos Vegetais/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Cognição/efeitos dos fármacos , Cognição/fisiologia , Transtornos Cognitivos/psicologia , Feminino , Ginkgo biloba , Humanos , Masculino , Memória/efeitos dos fármacos , Memória/fisiologia , Pessoa de Meia-Idade , Fitoterapia , Índice de Gravidade de Doença , Síndrome , Resultado do TratamentoRESUMO
Mild Cognitive Impairment (MCI) means cognitive deterioration not yet causing disability or dementia. Aged patients with MCI constitute a group of high risk for Alzheimer disease and other types of dementia. Currently, there is no generally adopted approach to MCI management but medications with neuroprotective properties are presumed to be the most perspective. Presented are the results of a multicentral open-label clinical trial of vascular and neuroprotective drug tanakan (EGb 761). The study has shown the decrease of cognitive impairment, which was both clinically and statistically significant, in patients at early stages of vascular and neurodegenerative pathological process. Probable efficacy of long-term tanakan treatment in prevention of dementia is discussed.